Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALV-100 in Overweight/Obese Participants with or without Type 2 Diabetes
NCT07399678Phase 1Active, not recruiting
- Start
- Dec 2025
- Primary completion
- Oct 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ALV-100 in obesity and type 2 diabetes mellitus (T2DM) (10 cohorts). Primary endpoint: Safety and tolerability at Week 52. Started Dec 2025; status: active, not recruiting.
02
Drugs
ALV-100
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07399678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07399678.